TNF抑制剂治疗与强直性脊柱炎前葡萄膜炎发生:瑞典生物制剂登记研究
基于瑞典风湿病质量登记和全国患者登记,纳入1365例以阿达木单抗、依那西普或英夫利西单抗作为首个TNFi的强直性脊柱炎患者,比较治疗前后及不同药物间前葡萄膜炎发生率。结果显示阿达木单抗和英夫利西单抗治疗后总体AU率下降,依那西普则上升;在治疗前2年无AU的患者中,依那西普相比阿达木单抗和英夫利西单抗的AU风险显著更高。
要点
- 阿达木单抗和英夫利西单抗治疗后总体AU率较治疗前下降,依那西普则上升。
- 治疗前2年无AU患者中,依那西普较阿达木单抗AU风险显著升高(HR 3.86)。
- 依那西普较英夫利西单抗AU风险亦显著升高(HR 1.99)。
核心结论
- 阿达木单抗、依那西普和英夫利西单抗对强直性脊柱炎患者AU风险的影响存在差异,阿达木单抗/英夫利西单抗明显优于依那西普。
研究设计与样本
- 基于瑞典风湿病质量登记和瑞典全国患者登记的真实世界队列研究,纳入2003年1月至2010年12月以阿达木单抗、依那西普或英夫利西单抗作为首个TNFi的强直性脊柱炎患者1365例(阿达木单抗406例,依那西普354例,英夫利西单抗605例)。
主要发现
- 与治疗前相比,阿达木单抗和英夫利西单抗治疗后总体AU率下降,依那西普治疗后总体AU率上升。
- 在治疗前2年内无AU的1127例患者中,依那西普对比阿达木单抗的AU调整HR为3.86(95%CI 1.85至8.06)。
- 在治疗前2年内无AU的1127例患者中,依那西普对比英夫利西单抗的AU调整HR为1.99(95%CI 1.23至3.22)。
- 英夫利西单抗对比阿达木单抗的HR无统计学意义。
关键数值与推荐
- AU发生率基于国际疾病分类第10版AU编码的眼科医生访视记录。
- 比较各TNFi治疗前2年与治疗开始后前2年的AU发生率。
- 在治疗前2年无AU的患者亚组中比较首次AU事件风险。
临床怎么用
- 对于强直性脊柱炎患者,选择TNFi时需考虑其对前葡萄膜炎风险的不同影响,阿达木单抗或英夫利西单抗可能优于依那西普。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tumour necrosis factor-α inhibitor (TNFi) treatment has been shown to reduce the rates of anterior uveitis (AU) in patients with ankylosing spondylitis (AS). Our objective was to compare the effect of adalimumab (ADA), etanercept (ETN) and infliximab (IFX) on AU occurrence in AS, using real-world data. METHODS: Patients with AS starting ADA, ETN or IFX as their first TNFi from January 2003 to December 2010 were extracted from the Swedish Rheumatology Quality Register. AU rates, based on visits to an ophthalmologist with International Classification of Diseases 10 codes for AU, were obtained by linkage to the Swedish National Patient Register. For each TNFi, AU rates 2 years before TNFi start and for the first 2 years on TNFi treatment were compared. In the subgroup of patients who were AU-free during the 2 years before TNFi start, we also compared the risk of a first AU event. RESULTS: 1365 patients with AS were included (406 ADA, 354 ETN, 605 IFX). Compared with pretreatment rates, we noted a reduction in overall AU rates for ADA and IFX, and an increase for ETN. The adjusted HRs for AU in 1127 patients who were free of AU in the last 2 years before TNFi start were significantly higher for ETN versus ADA (HR: 3.86 95% CI 1.85 to 8.06) and ETN versus IFX (HR: 1.99, 95% CI 1.23 to 3.22), while the HR for IFX versus ADA was not statistically significant. CONCLUSIONS: The results suggest differences in effect on AU risk between ADA, ETN and IFX, with a clear advantage for ADA/IFX over ETN.
引用
- Lie E, Lindström U, Zverkova-Sandström T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017. PMID: 28254789. doi:10.1136/annrheumdis-2016-210931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。